55 related articles for article (PubMed ID: 9507668)
1. Synthesis of 5-membered ring-type compounds as potential cholecystokinin receptor ligands.
Pentassuglia G; Araldi GL; Donati D; Feriani A; Oliosi B; Pasquarello A; Ursini A
Farmaco; 1997 Oct; 52(10):573-81. PubMed ID: 9507668
[TBL] [Abstract][Full Text] [Related]
2. Conformationally constrained CCK8 analogues obtained from a rationally designed peptide library as ligands for cholecystokinin type B receptor.
De Luca S; Saviano M; Della Moglie R; Digilio G; Bracco C; Aloj L; Tarallo L; Pedone C; Morelli G
ChemMedChem; 2006 Sep; 1(9):997-1006. PubMed ID: 16915602
[TBL] [Abstract][Full Text] [Related]
3. Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.
Gigoux V; Maigret B; Escrieut C; Silvente-Poirot S; Bouisson M; Fehrentz JA; Moroder L; Gully D; Martinez J; Vaysse N; Fourmy AD
Protein Sci; 1999 Nov; 8(11):2347-54. PubMed ID: 10595537
[TBL] [Abstract][Full Text] [Related]
4. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
5. Phenylpiperazinylmethylheterocycle derivatives: synthesis and dopamine receptor binding profiles.
Abadi AH
Arch Pharm (Weinheim); 2004 Jul; 337(7):383-90. PubMed ID: 15237388
[TBL] [Abstract][Full Text] [Related]
6. 5-Substituted imidazole-4-acetic acid analogues: synthesis, modeling, and pharmacological characterization of a series of novel gamma-aminobutyric acid(C) receptor agonists.
Madsen C; Jensen AA; Liljefors T; Kristiansen U; Nielsen B; Hansen CP; Larsen M; Ebert B; Bang-Andersen B; Krogsgaard-Larsen P; Frølund B
J Med Chem; 2007 Aug; 50(17):4147-61. PubMed ID: 17655213
[TBL] [Abstract][Full Text] [Related]
7. Peptide/benzodiazepine hybrids as ligands of CCK(A) and CCK(B) receptors.
Escherich A; Lutz J; Escrieut C; Fourmy D; van Neuren AS; Müller G; Schafferhans A; Klebe G; Moroder L
Biopolymers; 2000-2001; 56(2):55-76. PubMed ID: 11592053
[TBL] [Abstract][Full Text] [Related]
8. Radiolabeling approaches for cholecystokinin B receptor imaging.
Aloj L; Panico MR; Caracó C; Zannetti A; Del Vecchio S; Di Nuzzo C; Arra C; Morelli G; Tesauro D; De Luca S; Pedone C; Salvatore M
Biopolymers; 2002; 66(6):370-80. PubMed ID: 12658724
[TBL] [Abstract][Full Text] [Related]
9. Structure and activity studies on glycine receptor ligands. Part 5. Diphenyl imidazolin-4-one glycinamides.
Kieć-Kononowicz K; Karolak-Wojciechowska J
Acta Pol Pharm; 1998; 55(5):389-96. PubMed ID: 9921117
[TBL] [Abstract][Full Text] [Related]
10. [Cholecystokinin receptors. A target for tomorrow's psychopharmaceuticals?].
Zachrisson O; Lindefors N
Lakartidningen; 1996 Mar; 93(13):1225-7. PubMed ID: 8656838
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT(1) angiotensin II receptor antagonists based on the 4-phenylquinoline structure.
Cappelli A; Pericot Mohr Gl Gl; Gallelli A; Rizzo M; Anzini M; Vomero S; Mennuni L; Ferrari F; Makovec F; Menziani MC; De Benedetti PG; Giorgi G
J Med Chem; 2004 May; 47(10):2574-86. PubMed ID: 15115399
[TBL] [Abstract][Full Text] [Related]
12. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of cyclic and branched peptide analogues as ligands for cholecystokinin type 1 receptor.
De Luca S; De Capua A; Saviano M; Della Moglie R; Aloj L; Tarallo L; Pedone C; Morelli G
Bioorg Med Chem; 2007 Sep; 15(17):5845-53. PubMed ID: 17562367
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and three-dimensional quantitative structure-activity relationship analysis of H3 receptor antagonists containing a neutral heterocyclic polar group.
Rivara S; Mor M; Bordi F; Silva C; Zuliani V; Vacondio F; Morini G; Plazzi PV; Carrupt PA; Testa B
Drug Des Discov; 2003; 18(2-3):65-79. PubMed ID: 14675944
[TBL] [Abstract][Full Text] [Related]
15. Optimization of the in vitro and in vivo properties of a novel series of 2,4,5-trisubstituted imidazoles as potent cholecystokinin-2 (CCK2) antagonists.
Buck IM; Black JW; Cooke T; Dunstone DJ; Gaffen JD; Griffin EP; Harper EA; Hull RA; Kalindjian SB; Lilley EJ; Linney ID; Low CM; McDonald IM; Pether MJ; Roberts SP; Shankley NP; Shaxted ME; Steel KI; Sykes DA; Tozer MJ; Watt GF; Walker MK; Wright L; Wright PT
J Med Chem; 2005 Nov; 48(22):6803-12. PubMed ID: 16250639
[TBL] [Abstract][Full Text] [Related]
16. Diether derivatives of homo- or substituted piperidines as non-imidazole histamine H3 receptor ligands.
Łazewska D; Kuder K; Ligneau X; Camelin JC; Schunack W; Stark H; Kieć-Kononowicz K
Bioorg Med Chem; 2009 Apr; 17(8):3037-42. PubMed ID: 19329325
[TBL] [Abstract][Full Text] [Related]
17. Glycine derivatives of imidazolones as potential ligands of glycine binding site of NMDA receptors. Part 1.
Kieć-Kononowicz K; Karolak-Wojciechowska J; Handzlik J
Acta Pol Pharm; 1998; 55(5):381-8. PubMed ID: 9921116
[TBL] [Abstract][Full Text] [Related]
18. Cholecystokinin antagonists: pharmacological and therapeutic potential.
Herranz R
Med Res Rev; 2003 Sep; 23(5):559-605. PubMed ID: 12789687
[TBL] [Abstract][Full Text] [Related]
19. Scaffold hopping with molecular field points: identification of a cholecystokinin-2 (CCK2) receptor pharmacophore and its use in the design of a prototypical series of pyrrole- and imidazole-based CCK2 antagonists.
Low CM; Buck IM; Cooke T; Cushnir JR; Kalindjian SB; Kotecha A; Pether MJ; Shankley NP; Vinter JG; Wright L
J Med Chem; 2005 Nov; 48(22):6790-802. PubMed ID: 16250638
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and structure-activity investigation of iodinated arylhydantoins and arylthiohydantoins for development as androgen receptor radioligands.
Van Dort ME; Jung YW
Bioorg Med Chem Lett; 2004 Nov; 14(21):5285-8. PubMed ID: 15454212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
